Myriad Genetics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Glenview Capital Management and Larry Robbins have filed an amended Schedule 13G, reporting no beneficial ownership of Myriad Genetics Inc. common stock as of June 30, 2026.
NASDAQ
State Street Corporation has disclosed beneficial ownership of 5.3% of Myriad Genetics Inc. common stock as of June 30, 2026.
NASDAQ
State Street Corporation has reported beneficial ownership of 4.7% of Myriad Genetics Inc. common stock as of March 31, 2026.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 7,976,163 shares, representing 8.5% of Myriad Genetics Inc.'s common stock.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Myriad Genetics Inc. following an internal realignment.
NASDAQ
Millennium Management LLC and affiliated entities, including Israel A. Englander, have disclosed a combined beneficial ownership of 7.2% in Myriad Genetics, Inc. common stock.
NASDAQ
State Street Corporation has reported a 6.4% beneficial ownership stake in Myriad Genetics Inc. common stock as of December 31, 2025.
NASDAQ
Glenview Capital Management and Larry Robbins have reported a 5.3% passive beneficial ownership stake in Myriad Genetics Inc. common stock.
NASDAQ
Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Myriad Genetics, Inc.
NASDAQ
Barclays PLC has reported a 4.23% beneficial ownership stake in Myriad Genetics Inc. common stock as of September 30, 2025.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a beneficial ownership of 8.47% in Myriad Genetics Inc. common stock.
NASDAQ
Disciplined Growth Investors, Inc. has reported a 0.8% passive ownership stake in Myriad Genetics Inc. common stock.
NASDAQ
Barclays PLC has reported a beneficial ownership of 5.31% in Myriad Genetics Inc., totaling 4,899,951 common shares, held for ordinary business purposes.
NASDAQ
SCHEDULE 13G/A: Wellington Management Divests Myriad Genetics Stake
Wellington Management Group and its affiliates have reported a 0.0% beneficial ownership in Myriad Genetics, Inc. common stock, indicating a complete divestment or reduction below reporting thresholds.
NASDAQ
SCHEDULE 13G/A: Millennium Funds Boost Myriad Genetics Stake
Millennium Management and affiliated entities have increased their passive beneficial ownership in Myriad Genetics, Inc. to 5.3% of common stock.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 10.04% beneficial ownership stake in Myriad Genetics Inc. as of June 30, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 15.3% beneficial ownership stake in Myriad Genetics Inc., totaling 14,105,009 shares of common stock.
NASDAQ
Disciplined Growth Investors, Inc. has filed a Schedule 13G, revealing a 5.1% beneficial ownership stake in Myriad Genetics Inc. as of March 31, 2025.
NASDAQ
Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 5.0% beneficial ownership stake in Myriad Genetics, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Camber Capital Management LP and Stephen DuBois Disclose 3.41% Stake in Myriad Genetics Inc.
Camber Capital Management LP and Stephen DuBois have disclosed a shared beneficial ownership of 3.41% in Myriad Genetics Inc., totaling 3,100,000 shares of common stock.
NASDAQ
Wellington Management Group LLP and its affiliated entities have filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in Myriad Genetics, Inc. as of December 31, 2024.